Tivanisiran - Sylentis

Drug Profile

Tivanisiran - Sylentis

Alternative Names: SYL-1001; SYL-1001 DP

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sylentis
  • Class Analgesics; Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dry eyes
  • Phase II Ocular pain

Most Recent Events

  • 19 Oct 2017 Phase-III clinical trials in Dry eyes in Germany, Italy, Portugal (Ophthalmic) before October 2017
  • 05 Jun 2017 Sylentis plans a phase III trial for Dry eyes in USA
  • 18 May 2017 Phase-III clinical trials in Dry eyes in Estonia (Ophthalmic) (NCT03108664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top